|Daily Range||166.00p - 170.00p|
|52-Week Range||0.00p - 170.00p|
|Dividend (Yield)||0.00p (0.0%)|
|Average Daily Volume||0|
|Current FY EPS||0.00p|
AbbVie and Gilead are often compared because of their competing hepatitis C drugs. These two biopharmas nevertheless have fundamentally different core areas of expertise and approaches to drug development. And these differences give AbbVie a better long-term outlook than Gilead.
Stobart, Lonrho, and Bloomsbury Publishing are all in a slump.